Download App
Help CenterSubscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Polar Pharma India Ltd (523333)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 523333 NSE: Rubber Products | Small Cap | Polar Pharma India Share Price

BSE Share Price
Not Listed

Polar Pharma India Ltd (523333)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 523333 NSE: Rubber Products | Small Cap | Polar Pharma India Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹1 Cr.
Current Price
₹0
52-Week Low / High
₹1 / 1
TTM EPS
₹-11
TTM Sales
₹10.9 Cr.
Book Value per Share
₹-78.9
P/E Ratio
0.00
Industry PE
22.9
Price to Book (P/B)
-0.01
Price to Sales (P/S)
0.09
EV/EBITDA
58.16
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
0.00%
Return on Capital Employed (ROCE)
-0.93%
Return on Assets (ROA)
-44.85%
Operating Profit Margin
17.9%
Net Profit Margin
-124.62%
Gross Profit Margin
-104.1%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
48.49%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
29.75%
Pledged shares (%) of Promoter's holding (%)
93.93%
Reserves
₹-109 Cr.
Equity
₹12.3 Cr.
Face Value
₹10
All Time Low / High
₹0.79 / 80.00

Polar Pharma India stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation ⓘ

Mar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12TTM
ROCE % ⓘ6%9.6%3%26.5%-17.3%-3.8%-176.2%-21.1%-0.9%-20.3%-

Growth Parameters ⓘ
Sales ⓘ49.143.335.24618.925.90.3010.916.29
Sales YoY Gr.--11.8%-18.8%30.9%-59%37%-99%-88.5%36,266.7%48.5%-
Adj EPS ⓘ00.1-4.4-6.8-5.3-1.8-30.5-13.1-11-15.4-16.6
YoY Gr.-550%-3507.7%NANANANANANANA-
BVPS (₹) ⓘ6.26.62.69.12.90.8-54.6-67.7-78.7-94.1-103.6
Adj Net
Profit ⓘ		00.2-5.3-8.3-6.5-2.3-37.4-16.1-13.5-18.9-20
Cash Flow from Ops. ⓘ3.6-0.43.820.5-6.46.1-40.52.4-0.90.7-
Debt/CF from Ops. ⓘ14.6-138.214.81.9-76.8-2.143-128194.4-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ-11.6%-3%296.4%48.5%
Adj EPS ⓘ-309.3%NANANA
BVPSⓘ-235.2%-300.8%NANA
Share Price - - - -

Key Financial Parameters ⓘ

Mar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12TTM
Return on
Equity % ⓘ		0.21.4-67-92.3-74.1-64.2117.821.815.318.116.8
Op. Profit
Mgn % ⓘ		614.910.5-13.7-21.31-4123.7-7462.117.6-12.5-20.2
Net Profit
Mgn % ⓘ		0.10.4-15.1-18.1-34.5-8.7-14530.6-58751.4-123.7-116.7-217.1
Debt to
Equity ⓘ		6.15.912.83.29.418.6-1.3-1.3-1.2-1.2-
Working Cap
Days ⓘ		21524829523055228114,04367,29522313423
Cash Conv.
Cycle ⓘ		1301562031744452107,4687,812424-546

Valuation of Polar Pharma India - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *93.9393.9393.9393.9393.9393.9393.9393.9393.9393.93
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11
Sales18.8725.850.260.0310.86
Operating Expenses ⓘ + 23.2826.2411.262.018.92
Manufacturing Costs3.882.850.360.052.67
Material Costs10.1215.382.280.043.52
Employee Cost 5.324.892.950.251.48
Other Costs ⓘ 3.963.125.671.671.25
Operating Profit ⓘ -4.41-0.39-11.01-1.991.94
Operating Profit Margin (%) -23.4%-1.5%-4,280.2%-7,268.7%17.8%
Other Income ⓘ + 1.760.861.850.060.09
Exceptional Items ⓘ -3.490-4400
Interest ⓘ 4.765.243.8711.8513.33
Depreciation ⓘ 2.742.402.332.282.23
Profit Before Tax ⓘ -13.65-7.18-59.36-16.06-13.53
Tax ⓘ -4.52-4.478.6400
Profit After Tax -9.12-2.71-68-16.06-13.53
PAT Margin (%) -48.4%-10.5%-26,445.3%-58,722.0%-124.0%
Adjusted EPS (₹)-7.4-2.2-55.4-13.1-11.0
Dividend Payout Ratio (%)0%0%0%0%0%
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11

Equity and Liabilities

Shareholders Fund + 4.702.01-65.99-82.04-95.57
Share Capital ⓘ 13.5213.5213.5213.5213.52
Reserves ⓘ -8.82-11.51-79.51-95.56-109.09
Debt +45.0341.9585.01103.29117.48
Long Term Debt45.0341.9585.01103.29117.48
Short Term Debt00000
Minority Interest00000
Trade Payables1.460.850.852.263.57
Others Liabilities ⓘ 6.330.0412.345.326.03
Total Liabilities ⓘ 57.5244.8532.2228.8331.51

Fixed Assets

Net Fixed Assets ⓘ +31.1428.9026.1723.8421.66
Gross Block53.8753.6852.1551.9952.03
Accumulated Depreciation22.7324.7825.9728.1530.37
CWIP ⓘ 00000
Investments ⓘ 00000
Inventories12.713.490.690.463.52
Trade Receivables9.846.380.030.031.75
Cash Equivalents 0.811.740.480.470.50
Others Assets ⓘ 3.024.354.864.034.08
Total Assets ⓘ 57.5244.8532.2228.8331.51
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11
Cash Flow From Operating Activity ⓘ + -6.495.97-40.562.43-0.91
PBT ⓘ -10.15-7.18-15.36-16.06-13.53
Adjustment ⓘ 66.675.3414.5515.33
Changes in Working Capital ⓘ 1.096.5513.833.94-2.71
Tax Paid ⓘ 0.07-0.06-0.3800
Cash Flow From Investing Activity ⓘ + 0.940.620.380.01-0.05
Capex 0.18-0.090.080.01-0.05
Net Investments 00000
Others ⓘ 0.750.710.3000
Cash Flow From Financing Activity ⓘ + 4.02-5.6339.21-2.460.98
Net Proceeds from Shares ⓘ 00000
Net Proceeds from Borrowing ⓘ 4.07-5.36000
Interest Paid ⓘ -1.10-0.27-3.86-11.84-13.21
Dividend Paid ⓘ 00000
Others ⓘ 1.05043.069.3814.19
Net Cash Flow ⓘ -1.540.96-0.98-0.020.02
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11
Ratios
ROE (%)-264.35-128.56N/AN/AN/A
ROCE (%)-17.87-4.14N/AN/AN/A
Asset Turnover Ratio0.330.510.0100.36
PAT to CFO Conversion(x)N/AN/AN/AN/AN/A
Working Capital Days
Receivable Days190.30114.504,544.30350.9029.90
Inventory Days245.90114.402,963.907,634.1066.80
Payable Days52.5027.40136.300302.60

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Polar Pharma India Ltd FAQs

The current trading price of Polar Pharma India on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Polar Pharma India stood at ₹1.01 Cr

The latest P/E ratio of Polar Pharma India as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Polar Pharma India as of 31-Dec-1969 is -0.01.

The 52-week high of Polar Pharma India is ₹0.82 and the 52-week low is ₹0.82.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Polar Pharma India is ₹9.38 ( Cr.) .

Data is not available for this company.

No data found

No data found

About Polar Pharma India Ltd

Polar Pharma India, earlier known as ‘Palar Latex Ltd, was launched in the year 1988 and starterd the commercial production from its Balasore plant in 1991.

The company is committed to better, safer, more enjoyable life for the people. A company where people and technology continuously work hand in hand to evolve new standards of excellence in the field of male prophylactics. Where business values are re-defined with greater, global social concerns in mind. And the concern is turned into an action point in the company’s mission statement itself.

Today, Polar Pharma enjoys worldwide popularity and trust, as the key producer of high quality, male latex prophylactics in India. In fact, the company is one of the largest private sector condom manufacturing units in Asia, with an installed capacity of over 700 million pieces per annum.

A qualified team of professionals conduct regular checks for every batch produced to ensure consistency and quality of the finished products. PPIL has an in-house fully equipped product testing laboratory for quality checks

Product range of the company includes:

Contraceptives – condoms of the following types:

  • Adam- Lubricated Condoms
  • Seorita
  • Moments- Premium Condoms

Achievements/ recognition :

  • The company’s quality System has ISO:9001 accreditation received in the year 2000. and ISO 14001
  • The company has also received CE Certification in the year 2003.
  • Capexil Awards 2000-2001, 2002-2003 & 2005-2006
  • Capexil Certificate 
  • Star House Awards
You have 46 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now